Oramed Pharmaceuticals Statistics
Total Valuation
ORMP has a market cap or net worth of $156.93 million. The enterprise value is $23.49 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | Jan 16, 2026 |
Share Statistics
ORMP has 40.45 million shares outstanding. The number of shares has increased by 3.84% in one year.
| Current Share Class | 40.45M |
| Shares Outstanding | 40.45M |
| Shares Change (YoY) | +3.84% |
| Shares Change (QoQ) | -4.37% |
| Owned by Insiders (%) | 17.49% |
| Owned by Institutions (%) | 20.00% |
| Float | 30.21M |
Valuation Ratios
The trailing PE ratio is 2.59.
| PE Ratio | 2.59 |
| Forward PE | n/a |
| PS Ratio | 78.47 |
| Forward PS | n/a |
| PB Ratio | 0.76 |
| P/TBV Ratio | 0.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 0.37 |
| EV / Sales | 11.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.98, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.98 |
| Quick Ratio | 6.62 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 37.10% and return on invested capital (ROIC) is -17.91%.
| Return on Equity (ROE) | 37.10% |
| Return on Assets (ROA) | -4.88% |
| Return on Invested Capital (ROIC) | -17.91% |
| Return on Capital Employed (ROCE) | -7.12% |
| Weighted Average Cost of Capital (WACC) | 11.08% |
| Revenue Per Employee | $500,000 |
| Profits Per Employee | $15.81M |
| Employee Count | 4 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ORMP has paid $11.31 million in taxes.
| Income Tax | 11.31M |
| Effective Tax Rate | 15.01% |
Stock Price Statistics
The stock price has increased by +76.36% in the last 52 weeks. The beta is 1.25, so ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | +76.36% |
| 50-Day Moving Average | 3.44 |
| 200-Day Moving Average | 2.77 |
| Relative Strength Index (RSI) | 68.86 |
| Average Volume (20 Days) | 97,912 |
Short Selling Information
The latest short interest is 562,979, so 1.39% of the outstanding shares have been sold short.
| Short Interest | 562,979 |
| Short Previous Month | 541,599 |
| Short % of Shares Out | 1.39% |
| Short % of Float | 1.86% |
| Short Ratio (days to cover) | 4.47 |
Income Statement
In the last 12 months, ORMP had revenue of $2.00 million and earned $63.24 million in profits. Earnings per share was $1.50.
| Revenue | 2.00M |
| Gross Profit | 13,000 |
| Operating Income | -15.09M |
| Pretax Income | 75.32M |
| Net Income | 63.24M |
| EBITDA | -14.97M |
| EBIT | -15.09M |
| Earnings Per Share (EPS) | $1.50 |
Full Income StatementBalance Sheet
The company has $125.89 million in cash and $825,000 in debt, with a net cash position of $133.44 million or $3.30 per share.
| Cash & Cash Equivalents | 125.89M |
| Total Debt | 825,000 |
| Net Cash | 133.44M |
| Net Cash Per Share | $3.30 |
| Equity (Book Value) | 199.74M |
| Book Value Per Share | 5.09 |
| Working Capital | 114.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.15 million and capital expenditures -$9,000, giving a free cash flow of -$9.15 million.
| Operating Cash Flow | -9.15M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 121,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -9.15M |
| FCF Per Share | -$0.23 |
Full Cash Flow StatementMargins
Gross margin is 0.65%, with operating and profit margins of -754.40% and 3,202.50%.
| Gross Margin | 0.65% |
| Operating Margin | -754.40% |
| Pretax Margin | 3,766.20% |
| Profit Margin | 3,202.50% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $0.25, which amounts to a dividend yield of 6.44%.
| Dividend Per Share | $0.25 |
| Dividend Yield | 6.44% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 16.67% |
| Buyback Yield | -3.84% |
| Shareholder Yield | 2.60% |
| Earnings Yield | 40.30% |
| FCF Yield | -5.83% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on January 23, 2013. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jan 23, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
ORMP has an Altman Z-Score of 1.46 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.46 |
| Piotroski F-Score | 1 |
